

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	License
CONVEYING PARTY DATA	
Name	Execution Date
Flamel Technologies S.A.	04/25/2011
RECEIVING PARTY DATA	
Name:	Endo Pharmaceuticals Inc.
Street Address:	100 Endo Boulevard
City:	Chadds Ford
State/Country:	PENNSYLVANIA
Postal Code:	19317
PROPERTY NUMBERS Total: 4	
Property Type	Number
Patent Number:	6022562
Application Number:	11651577
Application Number:	11439432
Application Number:	12638739
CORRESPONDENCE DATA	
Fax Number:	(610)884-6965
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	610-387-6207
Email:	marchione.linda@endo.com
Correspondent Name:	Endo Pharmaceuticals Inc.
Address Line 1:	100 Endo Boulevard
Address Line 2:	Linda Marchione
Address Line 4:	Chadds Ford, PENNSYLVANIA 19317
NAME OF SUBMITTER:	Linda J. Marchione
Total Attachments: 5 source=License Agreement - Flamel and Endo Pharmaceuticals#page1.tif source=License Agreement - Flamel and Endo Pharmaceuticals#page2.tif source=License Agreement - Flamel and Endo Pharmaceuticals#page3.tif source=License Agreement - Flamel and Endo Pharmaceuticals#page4.tif source=License Agreement - Flamel and Endo Pharmaceuticals#page5.tif	

OP \$160.00 6022562

501629447

PATENT
REEL: 026766 FRAME: 0232

DEVELOPMENT AND LICENSE AGREEMENT

This Development and License Agreement (the "**Agreement**") is entered into as of April 25, 2011 (the "**Effective Date**") by and between Flamel Technologies S.A., a French corporation, having its principle place of business at 33 Avenue du Dr. Georges Levy, 69693 Venissieux Cedex, France, and its Affiliates ("**FLAMEL**"), and Endo Pharmaceuticals Inc., a Delaware corporation, having its principle place of business at 100 Endo Boulevard, Chadds Ford, Pennsylvania 19317, and its Affiliates ("**ENDO**"). ENDO and FLAMEL may be referred to herein individually as a "**Party**" or collectively as the "**Parties**."

RECITALS

WHEREAS, ENDO is engaged in the research, development, sale and marketing of pharmaceutical products;

WHEREAS, FLAMEL is engaged in the license, development and manufacture of pharmaceutical products and has developed certain proprietary technologies directed to tamper resistant formulation of opioid pharmaceuticals;

WHEREAS, ENDO and FLAMEL mutually desire: (i) FLAMEL to conduct formulation and analytical development work in consultation with ENDO and transfer certain technologies and pharmaceutical Products (as defined herein) to ENDO; and (ii) ENDO to obtain an exclusive license under FLAMEL Intellectual Property (as defined herein) and associated Know-How for the purposes of manufacturing, marketing, selling and distributing the Products in the Territory (as defined herein);

NOW THEREFORE, in consideration of the mutual covenants, representations and promises contained in this Agreement and for other good and valuable consideration, the receipt and sufficiency of which are acknowledged, FLAMEL and ENDO agree as follows:


ARTICLE 1

Definitions

- 1.1 "**Act**" shall mean the United States Federal Food, Drug and Cosmetic Act, as amended from time to time.
- 1.2 "**Affiliate**", as used herein, shall mean, as to any Party, any corporation, partnership or other entity that controls, is controlled by, or is under common control with, such Party. A corporation, partnership or other entity shall be deemed to control another if it owns, directly or indirectly, 50% (fifty percent) or more of the issued share capital, or it has the legal power to direct or cause the direction of the general management and policies of such other corporation, partnership or entity.
- 1.3 "**Agreement**" shall mean this Development and License Agreement entered into by and among FLAMEL and ENDO as of the Effective Date.
- 1.4 "**ANDA**" shall mean an abbreviated new drug application filed with the FDA pursuant to 21 U.S.C. 355(j).

IN WITNESS WHEREOF, each Party has caused this Agreement to be executed by its duly authorized representative as of the Effective Date.

FLAMEL TECHNOLOGIES S.A.

By: 

Name: Stephen H. Willard

Title: Chief Executive Officer

ENDO PHARMACEUTICALS INC.

By: 

Name: David P. Holveck

Title: President and Chief Executive Officer



[Signature Page to the Development And License Agreement]

Exhibit B - FLAMEL Patents

Flamel patents (Micropump® / Trigger Lock™)

1. Patent family "Medicinal and/or nutritional microcapsules for oral administration"

Application Number	Application Filing Date	Country	Title of Application	Status	Patent Number
FR 94 12759	18/10/94	France	Microcapsules médicamenteuses et/ou nutritionnelles pour administration per os	Patented	FR 2 725 623
PCT/FR95/01369	18/10/95	PCT	Medicinal and/or nutritional microcapsules for oral administration	N/A	N/A
08/544,208	17/10/95	USA	Medicinal and/or nutritional microcapsules for oral administration	Patented	US 6,022,562
333 864	17/10/95	Argentina	Medicinal and/or nutritional microcapsules for oral administration	Patented	255 431
01 01126	04/09/02	Argentina	Medicinal and/or nutritional microcapsules for oral administration	Patented	AR256244M
PI 9509286-2	18/10/95	Brazil	Medicinal and/or nutritional microcapsules for oral administration	Patented	PI 9509286.2
PI 9510807-6	28/11/05	Brazil	Medicinal and/or nutritional microcapsules for oral administration	Lapsed	N/A
CA2160762	17/10/95	Canada	Medicinal and/or nutritional microcapsules for oral administration	Patented	CA2160762
1913/DEL/1995	18/10/95	India	Medicinal and/or nutritional microcapsules for oral administration	Lapsed	184436
15/DEL/2000	11/01/00	India	Medicinal and/or nutritional microcapsules for oral administration	Patented	221334
115646	17/10/95	Israel	Medicinal and/or nutritional microcapsules for oral administration	Patented	115 646
513 006/95	18/10/95	Japan	Medicinal and/or nutritional microcapsules for oral administration	Patented	JP 4053589
95/8762	17/10/95	South Africa	Medicinal and/or nutritional microcapsules for oral administration	Patented	95/8762
95420286.7	18/10/95	EP/France	Medicinal and/or nutritional microcapsules for oral administration	Patented	EP 0709087
95420286.7	18/10/95	EP/Germany	Medicinal and/or nutritional microcapsules for oral administration	Patented	695 14 192.9
95420286.7	18/10/95	EP/Great Britain	Medicinal and/or nutritional microcapsules for oral administration	Patented	EP 0709087
95420286.7	18/10/95	EP/Italy	Medicinal and/or nutritional microcapsules for oral administration	Patented	EP 0709087
95420286.7	18/10/95	EP/Spain	Medicinal and/or nutritional microcapsules for oral administration	Patented	EP 0709087

2. Patent family "Oral dosage form comprising antimitotic system"

Application Number	Application Filing Date	Country	Title of Application	Status	Patent Number
PCT/EP2005/012721	13/06/05	PCT	Oral dosage form comprising an antimitotic system	lapsed	N/A
PCT/EP2006/062625	24/05/06	PCT	Oral dosage form comprising an antimitotic system	lapsed	N/A
2006259199	24/05/06	Australia	Oral dosage form comprising an antimitotic system	pending	
P1 0612084-9	24/05/06	Brazil	Oral dosage form comprising an antimitotic system	pending	
2 611 760	24/05/06	Canada	Oral dosage form comprising an antimitotic system	pending	
200680020991.3	24/05/06	China	Oral dosage form comprising an antimitotic system	pending	
0676328.2	24/05/06	Europe	Oral dosage form comprising an antimitotic system	pending	
187475	24/05/06	Israel	Oral dosage form comprising an antimitotic system	pending	
9257/DELNP/2007	24/05/06	India	Oral dosage form comprising an antimitotic system	pending	
2008-515177	24/05/06	Japan	Oral dosage form comprising an antimitotic system	pending	
7029209/2007	24/05/06	South Korea	Oral dosage form comprising an antimitotic system	pending	
2007/015801	24/05/06	Mexico	Oral dosage form comprising an antimitotic system	pending	
200718549-9	24/05/06	Singapore	Oral dosage form comprising an antimitotic system	pending	
11/651,577	10/01/07	USA	Oral dosage form comprising an antimitotic system	pending	
2007/09835	24/05/06	South Africa	Oral dosage form comprising an antimitotic system	granted	2007/09835

3. Patent family "Anti-misuse microparticulate oral pharmaceutical form"

Application Number	Application Filing Date	Country	Title of Application	Status	Patent Number
FR 05 53437	10/11/05	France	Forme pharmaceutique orale microparticulaire anti-mesusage	pending	
60/735,182	10/11/05	USA	Anti-misuse microparticulate oral pharmaceutical form	lapsed	N/A
11/439,432	24/05/06	USA	Anti-misuse microparticulate oral pharmaceutical form	pending	
12/638,739	15/12/09	USA	Anti-misuse microparticulate oral pharmaceutical form	pending	
PCT/EP2006/062627	24/05/06	PCT	Anti-misuse microparticulate oral pharmaceutical form	lapsed	N/A
2006311116	24/05/06	Australia	Anti-misuse microparticulate oral pharmaceutical form	pending	
PI 0618502-9	24/05/06	Brazil	Anti-misuse microparticulate oral pharmaceutical form	pending	
2 627 058	24/05/06	Canada	Anti-misuse microparticulate oral pharmaceutical form	pending	
200680042236.5	24/05/06	China	Anti-misuse microparticulate oral pharmaceutical form	pending	
06763289.3	24/05/06	Europe	Anti-misuse microparticulate oral pharmaceutical form	pending	
190749	24/05/06	Israel	Anti-misuse microparticulate oral pharmaceutical form	pending	
754/MUMNP/2008	24/05/06	India	Anti-misuse microparticulate oral pharmaceutical form	pending	
2008-539368	24/05/06	Japan	Anti-misuse microparticulate oral pharmaceutical form	pending	
7013970/2008	24/05/06	South Korea	Anti-misuse microparticulate oral pharmaceutical form	pending	
MX/a/2008/006042	24/05/06	Mexico	Anti-misuse microparticulate oral pharmaceutical form	pending	
200803437-3	24/05/06	Singapore	Anti-misuse microparticulate oral pharmaceutical form	pending	
2008/03140	24/05/06	South Africa	Anti-misuse microparticulate oral pharmaceutical form	granted	200803140